Earnings summaries and quarterly performance for Jade Biosciences.
Research analysts covering Jade Biosciences.
Recent press releases and 8-K filings for JBIO.
Jade Biosciences Provides Pipeline and Financial Update at J.P. Morgan Healthcare Conference
JBIO
New Projects/Investments
Guidance Update
Product Launch
- Jade Biosciences, launched in mid-2024, is focused on developing best-in-class therapeutics for autoimmune diseases, with three programs in its pipeline.
- The lead program, Jade 101 (anti-APRIL for IgA nephropathy), completed Phase 1 enrollment last year and expects data disclosure in H1 2026, with plans to dose the first patient in Phase 2 around mid-2026 and data in 2027. This program aims for best-in-class efficacy and Q8 week dosing, targeting a U.S. IgA nephropathy market opportunity initially estimated at $10 billion+, which some analysts now suggest could be $40 billion.
- Jade 201 (anti-BAFF receptor) is scheduled to begin a Phase 1 first-in-human study in Q2 2026, with data anticipated in 2027. A third, undisclosed program is expected to enter the clinic in H1 2027.
- The company closed last year with $336 million in capital, providing funding for operations across its three programs into H1 2028.
Jan 15, 2026, 7:15 PM
Jade Biosciences Updates on Autoimmune Pipeline and Market Opportunity at J.P. Morgan Healthcare Conference
JBIO
Product Launch
New Projects/Investments
Guidance Update
- Jade Biosciences, launched in mid-2024, is advancing a pipeline of three autoimmune disease therapeutics, with its lead program, JADE101 (anti-APRIL for IgA nephropathy), expecting Phase I data in the first half of 2026 and Phase II dosing by mid-2026.
- JADE101 aims for best-in-class efficacy and a convenient Q8 week dosing schedule, targeting a rapidly expanding IgA nephropathy market estimated at $10 billion-plus in the U.S. alone, with some analysts projecting up to $40 billion.
- The company's second program, JADE201 (anti-BAFF receptor), is scheduled to begin Phase I in Q2 2026, and a third undisclosed program is expected to enter the clinic in the first half of 2027.
- Jade Biosciences reported $336 million in capital at the end of 2025, sufficient to fund operations for its three programs into the first half of 2028.
Jan 15, 2026, 7:15 PM
Jade Biosciences Outlines Clinical Development and Financial Runway
JBIO
New Projects/Investments
Guidance Update
- Jade Biosciences, launched in mid-2024, is focused on developing best-in-class therapeutics for autoimmune diseases.
- Its lead program, Jade 101 for IgA nephropathy, completed Phase 1 enrollment in 2025, with data expected in H1 2026 and Phase 2 patient dosing planned for mid-2026. The U.S. market opportunity for IgA nephropathy is estimated at $10 billion-plus, with some analysts suggesting $40 billion.
- The second program, Jade 201, an anti-BAFF receptor, is scheduled to begin a Phase 1 first-in-human study in Q2 2026, with data anticipated in 2027.
- The company reported $336 million in capital at the end of 2025, sufficient to fund operations for its three programs into the first half of 2028.
Jan 15, 2026, 7:15 PM
Jade Biosciences Outlines 2026 Objectives and Pipeline Strategy
JBIO
New Projects/Investments
Guidance Update
- Jade Biosciences expects to have approximately $336 million in cash, cash equivalents, and investments as of December 31, 2025, which is anticipated to fund operations into the first half of 2028.
- The company anticipates interim Phase 1 data for JADE101 in the first half of 2026 and expects to initiate a Phase 2 clinical trial for JADE101 in IgA nephropathy mid-2026.
- JADE201 is expected to begin a first-in-human study in rheumatoid arthritis patients in the second quarter of 2026, and JADE301 is expected to commence a Phase 1 clinical trial in the first half of 2027.
Jan 5, 2026, 12:17 PM
Jade Biosciences Announces $45 Million Private Placement
JBIO
New Projects/Investments
- Jade Biosciences, Inc. announced a private placement financing expected to generate approximately $45 million in gross proceeds.
- The company is selling 3,214,286 shares of its common stock at a price of $14.00 per share to BB Biotech.
- The private placement is expected to close on or about December 16, 2025.
- Net proceeds from the offering will be used to fund research and development, general corporate expenses, and working capital needs.
Dec 15, 2025, 12:11 PM
Jade Biosciences Announces $45 Million Private Placement
JBIO
New Projects/Investments
- Jade Biosciences, Inc. (JBIO) has entered into a securities purchase agreement with BB Biotech for a private placement financing, expected to generate approximately $45 million in gross proceeds.
- The company is selling an aggregate of 3,214,286 shares of its common stock at a purchase price of $14.00 per share.
- The private placement is anticipated to close on or about December 16, 2025, subject to customary closing conditions.
- The net proceeds from this financing are intended to fund research and development, general corporate expenses, and working capital needs.
Dec 15, 2025, 12:00 PM
Jade Management Discusses Clinical Pipeline and IgA Nephropathy Market
JBIO
New Projects/Investments
Product Launch
Guidance Update
- Jade (JBIO), founded in June 2024, is developing three assets, with its lead program, JADE101 (anti-APRIL for IgA nephropathy), having initiated a Phase I study in August 2025 and expecting a key readout in H1 2026.
- The company's pipeline includes JADE201 (targeting BAFF-R) anticipated to enter the clinic in H1 2026, and a third undisclosed program in H1 2027.
- Jade is well-resourced to fund all trials into H1 2028.
- Management views IgA nephropathy as a a $10 billion+ opportunity in the US alone, emphasizing the disease-modifying potential of anti-APRIL therapies and the importance of convenience through infrequent dosing for JADE101.
- The FDA is considering shortening eGFR confirmatory trials for iGAN from two years to one year, which could support efficient development of anti-APRIL mechanisms.
Nov 17, 2025, 3:30 PM
JBIO Provides Update on Autoimmune Pipeline and IgA Nephropathy Market at Jefferies Conference
JBIO
New Projects/Investments
Product Launch
- JBIO, founded in June 2024, is developing best-in-class therapeutics for autoimmune diseases, with its lead program, JADE101, an anti-APRIL for IgA nephropathy (iGAN).
- The company initiated a Phase I healthy volunteer study for JADE101 in August 2025, with a key readout anticipated in the first half of 2026.
- JADE101 targets the iGAN market, estimated at over $10 billion in the US alone, and aims for best-in-class convenience with infrequent dosing.
- JBIO is well-resourced to fund its three pipeline programs into the first half of 2028.
- The second program, JADE201 (targeting BAFF-R), is expected to enter the clinic in the first half of 2026, with a third undisclosed program planned for the first half of 2027.
Nov 17, 2025, 3:30 PM
Jade Biosciences Reports Q3 2025 Financial Results and Corporate Updates
JBIO
Earnings
New Projects/Investments
- Jade Biosciences reported a net loss of $25.2 million for the third quarter ended September 30, 2025, compared to a net loss of $16.3 million for the same period in 2024.
- Research and Development (R&D) expenses increased to $22.0 million in Q3 2025 from $13.6 million in Q3 2024, while General and Administrative (G&A) expenses rose to $5.4 million from $1.4 million over the same periods.
- The company completed a $135 million private placement, which is expected to extend its cash runway into the first half of 2028.
- Significant pipeline progress includes the initiation of a Phase 1 healthy volunteer study for JADE101, with interim data anticipated in the first half of 2026, and the unveiling of JADE201, with its first-in-human trial expected to commence in the first half of 2026.
- As of September 30, 2025, Jade Biosciences held $198.9 million in cash, cash equivalents, and investments.
Nov 14, 2025, 12:00 PM
Jade Biosciences Updates on Pipeline Progress and Financial Position
JBIO
New Projects/Investments
Guidance Update
Convertible Preferred Issuance
- Jade Biosciences reported a pro forma cash position of $326 million as of October 2025, providing a financial runway into 1H 2028.
- The company is advancing three key programs: JADE101 (anti-APRIL for IgAN) with interim data expected in 1H 2026, JADE201 (anti-BAFF-R for autoimmune diseases) with planned First-in-Human (FIH) in 1H 2026, and JADE-003 (undisclosed) with planned FIH in 1H 2027.
- JADE101 targets the IgA nephropathy (IgAN) market, estimated at over $10 billion in the U.S. alone, and is designed for superior potency, extended half-life, and infrequent dosing.
- As of October 6, 2025, Jade Biosciences had 67,394,380 total outstanding shares, including common stock, preferred stock (as converted), and pre-funded warrants.
Nov 13, 2025, 11:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more